{"formats":[{"name":"JSON","format":"json","url":"\/downloads\/2025\/code-json\/54.1-2928.2.json"},{"name":"Plain Text","format":"text","url":"\/downloads\/2025\/code-text\/54.1-2928.2.txt"},{"name":"XML","format":"xml","url":"\/downloads\/2025\/code-xml\/54.1-2928.2.xml"},{"name":"HTML","format":"html","url":"\/downloads\/2025\/code-html\/54.1-2928.2.html"}],"law_id":84522,"edition_id":1,"section_id":84522,"structure_id":15945,"section_number":"54.1-2928.2","catch_line":"Board to adopt regulations related to prescribing of opioids and buprenorphine","history":"2017, cc. 291, 682.","full_text":"The Board shall adopt regulations for the prescribing of opioids and products containing buprenorphine. Such regulations shall include guidelines for:\n\n1\n\nThe treatment of acute pain, which shall include (i) requirements for an appropriate patient history and evaluation, (ii) limitations on dosages or day supply of drugs prescribed, (iii) requirements for appropriate documentation in the patient’s health record, and (iv) a requirement that the prescriber request and review information contained in the Prescription Monitoring Program in accordance with § 54.1-2522.1;2\n\nThe treatment of chronic pain, which shall include, in addition to the requirements for treatment of acute pain set forth in subdivision 1, requirements for (i) development of a treatment plan for the patient, (ii) an agreement for treatment signed by the provider and the patient that includes permission to obtain urine drug screens, and (iii) periodic review of the treatment provided at specific intervals to determine the continued appropriateness of such treatment; and3\n\nThe use of buprenorphine in the treatment of addiction, including a requirement for referral to or consultation with a provider of substance abuse counseling in conjunction with treatment of opioid dependency with products containing buprenorphine.","order_by":null,"text":{"0":{"id":302913,"text":"The Board shall adopt regulations for the prescribing of opioids and products containing buprenorphine. Such regulations shall include guidelines for:","type":"section","prefixes":[""],"prefix":"","entire_prefix":"","prefix_anchor":"","level":1,"next_prefix":"1"},"1":{"id":302914,"text":"The treatment of acute pain, which shall include (i) requirements for an appropriate patient history and evaluation, (ii) limitations on dosages or day supply of drugs prescribed, (iii) requirements for appropriate documentation in the patient’s health record, and (iv) a requirement that the prescriber request and review information contained in the Prescription Monitoring Program in accordance with § 54.1-2522.1;","type":"section","prefixes":["1"],"prefix":"1","entire_prefix":"1","prefix_anchor":"1","level":1,"prior_prefix":"","next_prefix":"2"},"2":{"id":302915,"text":"The treatment of chronic pain, which shall include, in addition to the requirements for treatment of acute pain set forth in subdivision 1, requirements for (i) development of a treatment plan for the patient, (ii) an agreement for treatment signed by the provider and the patient that includes permission to obtain urine drug screens, and (iii) periodic review of the treatment provided at specific intervals to determine the continued appropriateness of such treatment; and","type":"section","prefixes":["2"],"prefix":"2","entire_prefix":"2","prefix_anchor":"2","level":1,"prior_prefix":"1","next_prefix":"3"},"3":{"id":302916,"text":"The use of buprenorphine in the treatment of addiction, including a requirement for referral to or consultation with a provider of substance abuse counseling in conjunction with treatment of opioid dependency with products containing buprenorphine.","type":"section","prefixes":["3"],"prefix":"3","entire_prefix":"3","prefix_anchor":"3","level":1,"prior_prefix":"2"}},"ancestry":[{"id":15945,"edition_id":1,"name":"Board of Medicine","identifier":"2","label":"article","depth":4,"order_by":1,"parent_id":12759,"metadata":{},"date_created":"2026-06-26 04:02:27","date_modified":"2026-06-26 04:02:27","permalink":{"id":242015,"object_type":"structure","relational_id":15945,"identifier":"2","token":"54.1\/III\/29\/2","url":"\/54.1\/III\/29\/2\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12759,"edition_id":1,"name":"Medicine and Other Healing Arts","identifier":"29","label":"chapter","depth":3,"order_by":1,"parent_id":12758,"metadata":{},"date_created":"2026-06-26 03:43:51","date_modified":"2026-06-26 03:43:51","permalink":{"id":241933,"object_type":"structure","relational_id":12759,"identifier":"29","token":"54.1\/III\/29","url":"\/54.1\/III\/29\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12758,"edition_id":1,"name":"Professions and Occupations Regulated by Boards Within the Department of Health Professions","identifier":"III","label":"subtitle","depth":2,"order_by":1,"parent_id":12754,"metadata":{},"date_created":"2026-06-26 03:43:51","date_modified":"2026-06-26 03:43:51","permalink":{"id":241105,"object_type":"structure","relational_id":12758,"identifier":"III","token":"54.1\/III","url":"\/54.1\/III\/","edition_id":1,"permalink":0,"preferred":1}},{"id":12754,"edition_id":1,"name":"Professions and Occupations","identifier":"54.1","label":"title","depth":1,"order_by":1,"parent_id":null,"metadata":{},"date_created":"2026-06-26 03:43:51","date_modified":"2026-06-26 03:43:51","permalink":{"id":239313,"object_type":"structure","relational_id":12754,"identifier":"54.1","token":"54.1","url":"\/54.1\/","edition_id":1,"permalink":0,"preferred":1}}],"structure_contents":[{"id":84959,"structure_id":15945,"section_number":"54.1-2911","catch_line":"Board; membership; terms of office; change of residence; executive director; etc","url":"\/54.1-2911\/","token":"54.1\/III\/29\/2\/54.1-2911","metadata":false},{"id":84827,"structure_id":15945,"section_number":"54.1-2912","catch_line":"Nominations","url":"\/54.1-2912\/","token":"54.1\/III\/29\/2\/54.1-2912","metadata":false},{"id":80842,"structure_id":15945,"section_number":"54.1-2912.1","catch_line":"Continued competency and office-based anesthesia requirements","url":"\/54.1-2912.1\/","token":"54.1\/III\/29\/2\/54.1-2912.1","metadata":false},{"id":76512,"structure_id":15945,"section_number":"54.1-2912.2","catch_line":"Board may endorse certain document","url":"\/54.1-2912.2\/","token":"54.1\/III\/29\/2\/54.1-2912.2","metadata":false},{"id":81436,"structure_id":15945,"section_number":"54.1-2912.3","catch_line":"Competency assessments of certain practitioners","url":"\/54.1-2912.3\/","token":"54.1\/III\/29\/2\/54.1-2912.3","metadata":false},{"id":70956,"structure_id":15945,"section_number":"54.1-2912.4","catch_line":"Board to post autism information","url":"\/54.1-2912.4\/","token":"54.1\/III\/29\/2\/54.1-2912.4","metadata":false},{"id":73769,"structure_id":15945,"section_number":"54.1-2912.5","catch_line":"Standard of care pertaining to prenatal and postnatal and other depression; Communication of information","url":"\/54.1-2912.5\/","token":"54.1\/III\/29\/2\/54.1-2912.5","metadata":false},{"id":73565,"structure_id":15945,"section_number":"54.1-2913","catch_line":"Repealed","url":"\/54.1-2913\/","token":"54.1\/III\/29\/2\/54.1-2913","metadata":false},{"id":63542,"structure_id":15945,"section_number":"54.1-2913.1","catch_line":"Acceptance of other examinations","url":"\/54.1-2913.1\/","token":"54.1\/III\/29\/2\/54.1-2913.1","metadata":false},{"id":70411,"structure_id":15945,"section_number":"54.1-2914","catch_line":"Sale of controlled substances and medical devices or appliances; requirements for vision care services","url":"\/54.1-2914\/","token":"54.1\/III\/29\/2\/54.1-2914","metadata":false},{"id":80430,"structure_id":15945,"section_number":"54.1-2915","catch_line":"Unprofessional conduct; grounds for refusal or disciplinary action","url":"\/54.1-2915\/","token":"54.1\/III\/29\/2\/54.1-2915","metadata":false},{"id":62035,"structure_id":15945,"section_number":"54.1-2916","catch_line":"Repealed","url":"\/54.1-2916\/","token":"54.1\/III\/29\/2\/54.1-2916","metadata":false},{"id":72288,"structure_id":15945,"section_number":"54.1-2917","catch_line":"Repealed","url":"\/54.1-2917\/","token":"54.1\/III\/29\/2\/54.1-2917","metadata":false},{"id":65537,"structure_id":15945,"section_number":"54.1-2918","catch_line":"Suspension or revocation for violation of facility licensing laws","url":"\/54.1-2918\/","token":"54.1\/III\/29\/2\/54.1-2918","metadata":false},{"id":83965,"structure_id":15945,"section_number":"54.1-2919","catch_line":"Repealed","url":"\/54.1-2919\/","token":"54.1\/III\/29\/2\/54.1-2919","metadata":false},{"id":74481,"structure_id":15945,"section_number":"54.1-2920","catch_line":"Notice and opportunity to be heard required before suspension or revocation of license; allegations to be in writing; practice pending appeal; notice to patients","url":"\/54.1-2920\/","token":"54.1\/III\/29\/2\/54.1-2920","metadata":false},{"id":82905,"structure_id":15945,"section_number":"54.1-2921","catch_line":"Repealed","url":"\/54.1-2921\/","token":"54.1\/III\/29\/2\/54.1-2921","metadata":false},{"id":73523,"structure_id":15945,"section_number":"54.1-2922","catch_line":"Repealed","url":"\/54.1-2922\/","token":"54.1\/III\/29\/2\/54.1-2922","metadata":false},{"id":77073,"structure_id":15945,"section_number":"54.1-2923.1","catch_line":"Repealed","url":"\/54.1-2923.1\/","token":"54.1\/III\/29\/2\/54.1-2923.1","metadata":false},{"id":87485,"structure_id":15945,"section_number":"54.1-2924","catch_line":"Repealed","url":"\/54.1-2924\/","token":"54.1\/III\/29\/2\/54.1-2924","metadata":false},{"id":65860,"structure_id":15945,"section_number":"54.1-2924.1","catch_line":"Expired","url":"\/54.1-2924.1\/","token":"54.1\/III\/29\/2\/54.1-2924.1","metadata":false},{"id":66883,"structure_id":15945,"section_number":"54.1-2925","catch_line":"Use of experts in disciplinary proceedings","url":"\/54.1-2925\/","token":"54.1\/III\/29\/2\/54.1-2925","metadata":false},{"id":62965,"structure_id":15945,"section_number":"54.1-2926","catch_line":"Powers of Board with respect to practitioners licensed to practice pharmacy","url":"\/54.1-2926\/","token":"54.1\/III\/29\/2\/54.1-2926","metadata":false},{"id":67353,"structure_id":15945,"section_number":"54.1-2927","catch_line":"Applicants from other states without reciprocity; temporary licenses or certificates for certain practitioners of the healing arts","url":"\/54.1-2927\/","token":"54.1\/III\/29\/2\/54.1-2927","metadata":false},{"id":85302,"structure_id":15945,"section_number":"54.1-2928","catch_line":"Repealed","url":"\/54.1-2928\/","token":"54.1\/III\/29\/2\/54.1-2928","metadata":false},{"id":67409,"structure_id":15945,"section_number":"54.1-2928.1","catch_line":"Restricted volunteer license","url":"\/54.1-2928.1\/","token":"54.1\/III\/29\/2\/54.1-2928.1","metadata":false},{"id":84522,"structure_id":15945,"section_number":"54.1-2928.2","catch_line":"Board to adopt regulations related to prescribing of opioids and buprenorphine","url":"\/54.1-2928.2\/","token":"54.1\/III\/29\/2\/54.1-2928.2","metadata":false},{"id":86062,"structure_id":15945,"section_number":"54.1-2928.3","catch_line":"Continuing learning activities","url":"\/54.1-2928.3\/","token":"54.1\/III\/29\/2\/54.1-2928.3","metadata":false}],"previous_section":{"id":67409,"structure_id":15945,"section_number":"54.1-2928.1","catch_line":"Restricted volunteer license","url":"\/54.1-2928.1\/","token":"54.1\/III\/29\/2\/54.1-2928.1","metadata":false},"next_section":{"id":86062,"structure_id":15945,"section_number":"54.1-2928.3","catch_line":"Continuing learning activities","url":"\/54.1-2928.3\/","token":"54.1\/III\/29\/2\/54.1-2928.3","metadata":false},"metadata":false,"official_url":"https:\/\/law.lis.virginia.gov\/vacode\/54.1-2928.2\/","history_text":"

This law was first created in 2017. The record of its establishment is cataloged in chapters 291<\/a> and 682<\/a> of that year\u2019s edition of \u201cActs of Assembly,\u201d the annual state publication listing all changes made to the Code of Virginia in that year.<\/p>","references":false,"refers_to":[{"id":72705,"section_number":"54.1-2522.1","catch_line":"(Effective July 1, 2027) Requirements of practitioners","order_by":null,"url":"\/54.1-2522.1\/"}],"permalink":{"id":242121,"object_type":"law","relational_id":84522,"identifier":"54.1-2928.2","token":"54.1\/III\/29\/2\/54.1-2928.2","url":"\/54.1-2928.2\/","edition_id":1,"permalink":0,"preferred":1},"url":"\/54.1-2928.2\/","token":"54.1\/III\/29\/2\/54.1-2928.2","dublin_core":{"Title":"Board to adopt regulations related to prescribing of opioids and buprenorphine","Type":"Text","Format":"text\/html","Identifier":"\u00a7 54.1-2928.2","Relation":"Code of Virginia"},"html":"\n\t\t\t\t\t\t

The Board<\/span> shall adopt regulations for the prescribing of opioids and products containing buprenorphine. Such regulations shall include guidelines for:<\/p><\/section>\n\t\t\t\t\t\t

1.<\/span> The treatment of acute pain, which shall include (i) requirements for an appropriate patient history and evaluation, (ii) limitations on dosages or day supply of drugs prescribed, (iii) requirements for appropriate documentation in the patient’s health record, and (iv) a requirement that the prescriber request and review information contained in the Prescription Monitoring Program in accordance with § 54.1-2522.1<\/a>; <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

2.<\/span> The treatment of chronic pain, which shall include, in addition to the requirements for treatment of acute pain set forth in subdivision 1, requirements for (i) development of a treatment plan for the patient, (ii) an agreement for treatment signed by the provider and the patient that includes permission to obtain urine drug screens, and (iii) periodic review of the treatment provided at specific intervals to determine the continued appropriateness of such treatment; and <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

3.<\/span> The use of buprenorphine in the treatment of addiction, including a requirement for referral to or consultation<\/span> with a provider of substance abuse counseling in conjunction with treatment of opioid dependency with products containing buprenorphine. <\/i><\/a><\/p><\/section>","plain_text":" CODE OF VIRGINIA\n\nBOARD TO ADOPT REGULATIONS RELATED TO PRESCRIBING OF OPIOIDS AND BUPRENORPHINE\n(\u00a7 54.1-2928.2)\n\nThe Board shall adopt regulations for the prescribing of opioids and products\ncontaining buprenorphine. Such regulations shall include guidelines for:\n\n1. The treatment of acute pain, which shall include (i) requirements for an\nappropriate patient history and evaluation, (ii) limitations on dosages or day\nsupply of drugs prescribed, (iii) requirements for appropriate documentation in\nthe patient’s health record, and (iv) a requirement that the prescriber\nrequest and review information contained in the Prescription Monitoring Program\nin accordance with § 54.1-2522.1;\n\n2. The treatment of chronic pain, which shall include, in addition to the\nrequirements for treatment of acute pain set forth in subdivision 1,\nrequirements for (i) development of a treatment plan for the patient, (ii) an\nagreement for treatment signed by the provider and the patient that includes\npermission to obtain urine drug screens, and (iii) periodic review of the\ntreatment provided at specific intervals to determine the continued\nappropriateness of such treatment; and\n\n3. The use of buprenorphine in the treatment of addiction, including a\nrequirement for referral to or consultation with a provider of substance abuse\ncounseling in conjunction with treatment of opioid dependency with products\ncontaining buprenorphine.\n\nHISTORY: 2017, cc. 291, 682.","edition":{"id":1,"name":"2025","slug":"2025","date_created":"2026-06-21 22:39:22","date_modified":"2026-06-21 22:39:22","current":1,"order_by":1,"last_import":null}}